Medicure sells Apricore stake, will see $105 mln in proceeds
Medicure Inc (TSX-V: MPH) has sold its interest in Apicore Inc, a U.S. developer and maker of active pharmaceutical ingredients and pharmaceuticals, to an unidentified buyer. The sale will provide the Winnipeg specialty pharmaceutical company with net proceeds of about US$105 million. Medicure acquired Apicore over 2014-2017, assuming a majority position last year with the help of a $60 million loan provided by Canadian specialty finance firm Crown Capital Partners and the Ontario Pension Board. Prior to then, Signet Healthcare Partners and other investors helped fund the acquisition.
3 October 2017•3 mins read
